PharmaShots Weekly Snapshot (January 06-10, 2020)

  1. Nektar Therapeutics Signs a Clinical Trial Collaboration with Bristol-Myers Squibb

Published: Jan 10, 2020 | Tags: Nektar Therapeutics, Signs, Clinical Trial, Collaboration, Bristol-Myers Squibb

2. Eli Lilly to Acquire Dermira for $1.1B

Published: Jan 10, 2020 | Tags: Eli Lilly, Acquire, Dermira, $1.1B

3. Bayer Signs a Three Year Multi Target AI-based Agreement with Exscientia to Treat Cardiovascular and Oncology Diseases

Published: Jan 10, 2020 | Tags: Bayer, Signs, Three Year, AI-based, Agreement, Exscientia, Cardiovascular, Oncology Diseases

4.  Immunic Exercises its Worldwide Exclusive Option to License for IMU-856 with Daiichi Sankyo

Published: Jan 10, 2020 | Tags: Immunic, Exercises, Worldwide, Exclusive, Option to License, IMU-856, Daiichi Sankyo

5. Pfizer Signs an Exclusive Worldwide License Agreement with eFFECTOR to Develop Therapies for Cancer Indications

Published: Jan 10, 2020 | Tags: Pfizer, Signs, Exclusive, Worldwide, License Agreement, eFFECTOR, Develop, Therapies, Cancer Indications

6. Kaleido Signs a Collaboration with Janssen for Microbiome Metabolic Therapies (MMT)

Published: Jan 10, 2020 | Tags: Kaleido, Signs, Collaboration, Janssen, Microbiome Metabolic Therapies, MMT

7. Gilead Signs an Exclusive License Agreement with Rockefeller University for its Portfolio of HIV Abs

Published: Jan 10, 2020 | Tags: Gilead, Signs, Exclusive, License Agreement, Rockefeller University, HIV Abs

8. Biomed Collaborates with Merck & Co for Autoimmune Diseases

Published:  Jan 10, 2020 | Tags: BioMed, Collaborates, Merck & Co, Autoimmune Diseases

9. Evotec Signs a Five-Year Collaboration with Bayer to Develop Therapies for Polycystic Ovary Syndrome

Published: Jan 09, 2020 | Tags: Evotec, Signs, Five-Year Collaboration, Bayer, Develop, Therapies,  Polycystic Ovary Syndrome

10.  Almirall Signs an In-License Agreement with 23andMe for Multiple Inflammatory Diseases

Published: Jan 09, 2020 | Tags: Almirall, Signs, In-License Agreement, 23andMe, Multiple Inflammatory Diseases

11. Mylan Voluntarily Recalls Nationwide Three Lots of Nizatidine Capsules USP Due to Trace Amounts of NDMA (N-Nitrosodimethylamine)

Published: Jan 09, 2020 | Tags: Mylan, Voluntarily, Recalls, Nationwide, Three Lots, Nizatidine Capsules USP, NDMA (N-Nitrosodimethylamine)

12.  Merck & Co’s Keytruda (pembrolizumab) Receives the US FDA’s Approval for Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

Published: Jan 09, 2020 | Tags: Merck & Co’s, Keytruda, pembrolizumab, Receives, US, FDA, Approval, Patients, BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer

13. Veracyte Signs a Multi-Year Agreement with AstraZeneca

Published: Jan 09, 2020 | Tags: Veracyte, Signs, Multi-Year Agreement, AstraZeneca

14.  Gilead Signs a License Agreement with Xencor for its GS-9722 to Treat HIV

Published: Jan 08, 2020 | Tags: Gilead, Signs, License Agreement, Xencor, GS-9722, HIV

15. PhoreMost Signs a Multi-Project Drug Discovery Agreement with Boehringer Ingelheim

Published: Jan 08, 2020 | Tags: PhoreMost, Signs, Multi-Project, Drug Discovery Agreement, Boehringer Ingelheim

16. Abbott’s HeartMate 3 Heart Pump Receives the US FDA’s Approval for Patients to Avoid Open Heart Surgery

Published: Jan 08, 2020 | Tags:  Abbott, HeartMate 3 Heart Pump, Receives, US, FDA, Approval, Patients, Avoid Open Heart Surgery

17.  Innovent Signs a Clinical Trial Agreement with Sirnaomics to Treat Cancer and Fibrotic Diseases in the US

Published: Jan 08, 2020 | Tags: Innovent, Signs, Clinical Trial Agreement, Sirnaomics, Treat, Cancer, Fibrotic Diseases, US

18. Eagle Signs a Co-Promotion Agreement with Tyme for SM-88 to Treat Cancer

Published: Jan 08, 2020 | Tags: Eagle, Signs, Co-Promotion Agreement, Tyme, SM-88, Treat, Cancer

19.  MiNA Therapeutics Signs a Research Collaboration with AstraZeneca to Evaluate Therapies for Metabolic Diseases

Published: Jan 08, 2020 | Tags: MiNA Therapeutics, Signs, Research Collaboration, AstraZeneca, Evaluate, Therapies, Metabolic Diseases

20.  Bicycle Therapeutics Signs Clinical Development Partnership with Cancer Research UK for BT7401

Published: Jan 08, 2020 | Tags: Bicycle Therapeutics, Signs, Clinical Development Partnership, Cancer Research UK, BT7401

21. Evotec Expands its 2016 Agreement with Bristol-Myers Squibb

Published: Jan 07, 2020 | Tags: Evotec, Expands, 2016, Agreement, Bristol-Myers Squibb

22.  Mithra Signs a License Agreement with Alvogen for its Estelle in Hong Kong and Taiwan

Published: Jan 07, 2020 | Tags: Mithra, Signs, License Agreement, Alvogen, Estelle, Hong Kong, Taiwan

23.  Merck KGaA and Pfizer Report Results of Bavencio (avelumab) in P-III JAVELIN Bladder 100 Study for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Published: Jan 07, 2020 | Tags: Merck KGaA, Pfizer, Report, Results, Bavencio, avelumab, P-III, JAVELIN Bladder 100, Study, Patients, Locally Advanced, Metastatic Urothelial Carcinoma

24.  Mundipharma Signs an Exclusive Commercialization and Distribution Agreement with Biosolution in South Korea

Published: Jan 07, 2020 | Tags:  Mundipharma, Signs, Exclusive, Commercialization, Distribution, Agreement, Biosolution, South Korea

25.  Merck & Co Reports Results of Keytruda in P-III KEYNOTE-604 Trial in 1L Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Published: Jan 07, 2020 | Tags: Merck & Co, Reports, Results, Keytruda, P-III, KEYNOTE-604, Trial, 1L, Patients, Extensive Stage Small Cell Lung Cancer (ES-SCLC)

26. Sorrento’s Partner Mabpharm Files NDA to the NMPA for Infliximab Biosimilar in China

Published: Jan 07, 2020 | Tags: Sorrento, Partner, Mabpharm, Files, NDA, NMPA, Infliximab, Biosimilar, China

27.  InxMed Signs a Clinical Trial Collaboration with Merck & Co for Patients with Pancreatic Cancer

Published: Jan 06, 2020 | Tags: InxMed, Signs, Clinical Trial Collaboration, Merck & Co, Patients, Pancreatic Cancer

28. Merck & Co Signs an Exclusive Worldwide License Agreement with Taiho and Astex to Develop Targeted Therapies

Published: Jan 06, 2020 | Tags: Merck & Co, Signs, Exclusive, Worldwide License Agreement, Taiho,  Astex, Develop, Targeted, Therapies

29.  I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients with Relapsed or Refractory Multiple Myeloma

Published: Jan 06, 2020 | Tags: I-Mab, Reports, Dosing, TJ202/MOR202, P-II, Trial, Relapsed or Refractory, Multiple Myeloma

30. AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) Receives NMPA’s Approval for Patients with Hyperkalaemia

Published: Jan 06, 2020 | Tags: AstraZeneca, Lokelma, sodium zirconium cyclosilicate, Receives, NMPA, Approval, Patients, Hyperkalaemia

31. Kyowa Kirin’s Istradefylline (KW-6002) Receives EMA’s MAA as an Adjunctive Treatment to Levodopa-Based Regimens in Adult with Parkinson’s disease Experiencing “Off” Time

Published: Jan 06, 2020 | Tags: Kyowa Kirin, Istradefylline, KW-6002, Receives, EMA, MAA, Adjunctive Treatment, Levodopa-Based Regimens, Adult, Parkinson’s disease, Experiencing, “Off” Time

32. AstraZeneca’s Farxiga (dapagliflozin) Receives the US FDA’s Priority Review Voucher for the Reduction of CV Risks and Death in Patients with Type-2 Diabetes

Published: Jan 06, 2020 | Tags: AstraZeneca, Farxiga, dapagliflozin, Receives, US, FDA, Priority Review Voucher, Reduction, CV Risks, Death, Patients, Type-2 Diabetes

33. BeiGene Signs an Exclusive Option and License Agreement with Leap Therapeutics for DKN-01

Published: Jan 06, 2020 | Tags: BeiGene, Signs, Exclusive, Option and License Agreement, Leap Therapeutics, DKN-01